• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Luna Innovations Retains Industry Veterans to Lead Strategy, Operations and Finance

    5/1/24 5:05:00 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $LUNA alert in real time by email

    Alex Davern and Kevin Ilcisin Join as Advisors to the Board of Directors

    John Roiko Appointed as Chief Financial Officer

    Board Announces Exploration of Strategic Alternatives

    Company Provides Update Related to Special Committee Independent Review

    Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that it has retained senior executives and industry veterans Alex Davern and Kevin Ilcisin as consultants to provide strategic advice and counsel with respect to the Company's operations and strategy. Mr. Davern and Mr. Ilcisin will report to Richard Roedel, the Company's Interim Executive Chairman and Interim President. The Company has also appointed finance executive John Roiko as Chief Financial Officer to succeed George Gomez-Quintero, who notified the Company on April 29, of his resignation from his position, which became effective today.

    "As we continue to grow our business and pursue our mission of delivering best in class solutions to our customers, we are pleased to have Alex and Kevin advise the Company and our leadership team," said Mr. Roedel. "Alex and Kevin bring deep experience in the area of test and measurement hardware and software solutions and have an excellent track record of delivering stockholder value. We are also pleased to have added John, a highly seasoned public company executive who brings decades of accounting and finance experience in addition to his sector expertise, and we look forward to leveraging his expertise to advance our financial operations."

    In addition, the Company's Board of Directors (the "Board") is initiating a review of strategic alternatives available to the Company in consultation with its financial and legal advisors. The Board has engaged Evercore to serve as its financial advisor. Mr. Davern and Mr. Ilcisin will play a leading role in the strategic review process and will begin their work with a full review of Luna's operations and strategy.

    "We are honored and excited to work with the dedicated and seasoned professionals at Luna who are focused on delivering solutions to Luna's marquee customer base," said Mr. Davern and Mr. Ilcisin. "With its cutting-edge fiber optic-based sensing technology, Luna has tremendous potential, and we look forward to leveraging the Company's industry leading position and exceptional talent to drive continued strong product development and providing our customers with exceptional service."

    Further, in connection with the Special Committee of the Board's continuing independent review into the Company's historical financial statements, Chief Technology Officer Brian Soller was terminated from his position for cause effective today, and the Company also terminated the employment of seven additional employees. The Board has also determined that former President and Chief Executive Officer, Scott Graeff, engaged in conduct that constituted "Cause" under his employment agreement, triggering certain clawback provisions in his separation agreement dated March 24, 2024.

    Biographies

    Alex Davern

    Alex Davern was previously the CEO of National Instruments, a leading provider of software-connected automated test and measurement systems, where he started working in 1994 and was a key member of the team that drove annual revenue from $100 million to more than $1.3 billion during his tenure which ended in 2020. He continued to serve as a Director of National Instruments until the Company was acquired by Emerson in October 2023.

    In 2021, Mr. Davern was appointed Chairman of ESI Group, a virtual prototyping and simulation software company, to lead a process to enhance the company's performance and strategic direction which culminated in a sale of ESI Group to Keysight Technologies in November 2023. Mr. Davern currently serves on the boards of directors for FARO Technologies and Cirrus Logic.

    During his tenure at National Instruments, Mr. Davern also served as President, COO, Executive Vice President, CFO, Treasurer, Senior Vice President, Corporate Controller, and International Controller. Before joining National Instruments, he worked in Europe and the U.S. for the international accounting firm Price Waterhouse LLP.

    Mr. Davern holds a bachelor's degree in commerce and a postgraduate diploma in professional accounting from University College Dublin in Ireland.

    Kevin Ilcisin

    Kevin Ilcisin is the co-founder of the advisory firm Juniper Strategies. Prior to founding Juniper, Mr. Ilcisin served as Senior Vice President of Strategy and Corporate Development at National Instruments where he led several acquisitions as well as the sale of National Instruments to Emerson. Prior to National Instruments, he was the Chief Technology officer of Tektronix, a subsidiary of Fortive, a spin-off of Danaher Corporation, where he managed strategic planning and technology growth initiatives.

    Mr. Ilcisin has also held several general management and technology executive roles in the semiconductor equipment, consumer electronics, and energy research industries, including start-ups and scale ups.

    Mr. Ilcisin holds a Ph.D. and M.A. degrees in Plasma Physics from Princeton University and B.Sc. in Electrical Engineering with Distinction from the University of Alberta.

    John Roiko

    John Roiko joined National Instruments in 1998 and most recently served as Chief Accounting Officer, overseeing National Instruments' global accounting organization. Mr. Roiko had previously served a number of senior financial roles at National Instruments, including as Vice President, Finance, and Interim Chief Financial Officer.

    Prior to joining National Instruments, Mr. Roiko worked as a product line controller for the defense division at Honeywell before moving to Emerson Process Management as the North Americas accounting manager. Mr. Roiko then pursued start-up opportunities as the Chief Financial Officer for Columbia Scientific and director of accounting for Arrowsmith Technologies.

    Mr. Roiko holds a bachelor's degree in Finance with a minor in Accounting from St. Cloud State University and a master's degree from Minnesota State University.

    Strategic Review

    Supported by Evercore, the Board will consider a wide range of options for the Company including, among other things, a potential sale, merger or other strategic transaction. There is no deadline or definitive timetable set for completion of the strategic alternatives process, and there is no assurance that this process will result in any specific transaction. There is also no assurance as to the specific terms or timing for any agreed transaction if one were to result. The Company does not plan to make further comment or disclosures regarding this review until such time as required by law or otherwise deemed appropriate.

    About Luna

    Luna Innovations Incorporated (www.lunainc.com) is a leader in optical technology, providing unique capabilities in high-performance, fiber optic-based, test products for the telecommunications industry and distributed fiber optic-based sensing for a multitude of industries. Luna's business model is designed to accelerate the process of bringing new and innovative technologies to market.

    Forward-Looking Statements

    This press release contains statements that constitute "forward-looking information" and "forward-looking statements" within the meaning of U.S. securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding the ongoing internal investigation, the timing of the Company's filings with the U.S. Securities and Exchange Commission and the issuance of restated financial statements, the Company's future performance and product development and the Company's exploration of strategic alternatives are forward-looking statements. Forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements, including the results of the ongoing internal investigations, the uncertainties inherent in management transitions, uncertainties associated with the exploration of strategic alternatives and such other risks and uncertainties described in Luna's filings with the U.S. Securities and Exchange Commission, including in Luna's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. Such filings are available on the SEC's website at www.sec.gov and on Luna's website at www.lunainc.com. The Company expressly disclaims any obligation or undertaking to update the forward-looking statements contained in this press release to reflect any change in its expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No assurance can be given that such future results will be achieved. Forward-looking statements speak only as of the date of this press release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240501041493/en/

    Get the next $LUNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LUNA

    DatePrice TargetRatingAnalyst
    7/28/2023$12.50Buy
    Stifel
    5/22/2023$10.00Buy
    Needham
    3/15/2023$8.00Outperform → Market Perform
    Northland Capital
    5/23/2022$8.00Market Perform → Outperform
    Northland Capital
    More analyst ratings

    $LUNA
    SEC Filings

    View All

    Luna Innovations Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

    1/27/25 10:26:44 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SCHEDULE 13G filed by Luna Innovations Incorporated

    SCHEDULE 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

    1/14/25 1:56:29 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

    1/6/25 8:30:40 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Luna Innovations Incorporated - Notice of Pendency and Proposed Settlement of Stockholder Derivative Action

    Luna Innovations Incorporated (OTC:LUNA), a global leader in advanced fiber-optic technology, today announced a Notice of Pendency and Proposed Settlement of Stockholder Derivative Action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216383469/en/View source version on businesswire.com: https://www.businesswire.com/news/home/20260216383469/en/ Investor Contact: Ryan Stewart, General Counsel Luna Innovations Incorporated Phone: (540) 769-8400 Email: [email protected]

    2/16/26 8:00:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations Reports Q3 2025 Results Including Continued Bookings Growth and Margin Expansion

    Luna Innovations Incorporated (OTC:LUNA) ("Luna" or the "Company"), a global leader in advanced fiber-optic technology, today announced preliminary unaudited financial results for the third quarter ended September 30, 2025. The Company reported continued growth in bookings, revenue, and positive cash generation. "Our third quarter performance reflects disciplined execution and sustained attractiveness of our core markets," said Kevin Ilcisin, President and Chief Executive Officer of Luna. "Both our Optical Communications and Sensing businesses delivered growth while we continued to improve margins and strengthen liquidity." Financial Highlights for the Third Quarter Ended September 30, 20

    11/4/25 8:00:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Announces Strong Start to 2025 with Substantial Bookings Growth

    Luna Innovations Incorporated (OTC:LUNA) ("Luna" or the "Company"), a global leader in advanced fiber optic-based technology, today announced select preliminary operating and financial metrics for the first quarter ended March 31, 2025, showcasing significant year-over-year bookings growth, continued gross margin expansion, and sustained execution on cost containment initiatives. "We are pleased to report a strong start to 2025, with sharp improvements in bookings, margin performance, and working capital management," said the Company's President, Chief Executive Officer, Kevin Ilcisin. "Our continued focus on operational discipline, customer alignment, and profitable growth is positioning

    5/20/25 8:48:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Spiegel Gary converted options into 10,672 shares, increasing direct ownership by 15% to 81,625 units (SEC Form 4)

    4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

    1/3/25 4:44:17 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Anderson N Leigh converted options into 19,869 shares, increasing direct ownership by 122% to 36,102 units (SEC Form 4)

    4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

    1/3/25 4:43:48 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Coe Pamela L converted options into 13,372 units of Common Stock (SEC Form 4)

    4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

    12/26/24 5:52:51 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Luna Innovations with a new price target

    Stifel initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $12.50

    7/28/23 7:35:40 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Needham initiated coverage on Luna Innovations with a new price target

    Needham initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $10.00

    5/22/23 7:57:49 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations downgraded by Northland Capital with a new price target

    Northland Capital downgraded Luna Innovations from Outperform to Market Perform and set a new price target of $8.00

    3/15/23 8:52:49 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Financials

    Live finance-specific insights

    View All

    Luna Innovations Reports Q3 2025 Results Including Continued Bookings Growth and Margin Expansion

    Luna Innovations Incorporated (OTC:LUNA) ("Luna" or the "Company"), a global leader in advanced fiber-optic technology, today announced preliminary unaudited financial results for the third quarter ended September 30, 2025. The Company reported continued growth in bookings, revenue, and positive cash generation. "Our third quarter performance reflects disciplined execution and sustained attractiveness of our core markets," said Kevin Ilcisin, President and Chief Executive Officer of Luna. "Both our Optical Communications and Sensing businesses delivered growth while we continued to improve margins and strengthen liquidity." Financial Highlights for the Third Quarter Ended September 30, 20

    11/4/25 8:00:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations to Delay Release of Fourth Quarter and Full Year 2023 Financial Results

    Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced it will delay the release of its fourth quarter and fiscal year 2023 financial results and the subsequent conference call. A Special Committee of the Company's Board of Directors is conducting an independent review, with the assistance of external legal and financial advisors, of certain transactions for which revenue was recognized in the second and third quarters of 2023 that did not qualify for revenue recognition under U.S. generally accepted accounting principles. The Special Committee is examining the circumstances surrounding these issues and is eva

    3/12/24 4:20:00 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Announces $50 Million Strategic Investment from White Hat Capital Partners

    Investment Proceeds Used to Fund Silixa Acquisition and Enhance Luna's Financial Flexibility to Pursue Strategic Growth Initiatives Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced a $50 million investment by White Hat Capital Partners ("White Hat"), an investment firm focused on sustainable value creation in technology companies serving mission-critical applications. Proceeds from this strategic investment were partially used to fund the acquisition of Silixa, also announced today, and related transaction costs in the aggregate amount of approximately $25 million. Remaining proceeds were used to repay the Company's o

    12/21/23 9:34:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Leadership Updates

    Live Leadership Updates

    View All

    Luna Innovations Announces Baker Tilly as New Independent Auditor

    Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

    4/2/25 8:52:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Announces Resignation of Pamela Coe

    Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that, Pamela Coe, a member of the Board of Directors (the "Board"), will be retiring from the Luna board effective today. Ms. Coe was elected to the Board in May 2021 for a three-year term. "We are very grateful for Pam's notable contributions and leadership throughout her time on the Board," said Barry Phelps, Chairman of the Board of the Company. "Her expertise, focus and commitment have been instrumental in guiding Luna. We wish Pam all the best in her future endeavors." About Luna Luna Innovations Incorporated (www.lunainc.com) is a leader in optic

    12/27/24 4:40:00 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations Announces CFO Transition: Names William Phelan as Chief Financial Officer and Chief Accounting Officer

    Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the appointment of William L. Phelan as its new Chief Financial Officer and Chief Accounting Officer, effective immediately. Mr. Phelan succeeds John Roiko, who joined Luna out of retirement in May 2024 and played a key role in establishing a resilient foundation for Luna's future growth. Following the appointment of Mr. Phelan, Mr. Roiko will shift to a consulting role to support the ongoing restatement process. "We are delighted to welcome Bill to the Luna leadership team," said Kevin Ilcisin, President and CEO of Luna. "Bill's highly relevant experience will be instrume

    10/16/24 4:30:00 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Luna Innovations Incorporated

    SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

    11/14/24 12:32:28 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by Luna Innovations Incorporated

    SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

    11/14/24 8:39:20 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by Luna Innovations Incorporated

    SC 13G/A - LUNA INNOVATIONS INC (0001239819) (Subject)

    11/12/24 4:02:00 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care